Literature DB >> 12637401

Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis.

Timothy R Sterling1, Harold P Lehmann, Thomas R Frieden.   

Abstract

OBJECTIVE: This study sought to determine the impact of the World Health Organization's directly observed treatment strategy (DOTS) compared with that of DOTS-plus on tuberculosis deaths, mainly in the developing world.
DESIGN: Decision analysis with Monte Carlo simulation of a Markov decision tree. DATA SOURCES: People with smear positive pulmonary tuberculosis. DATA ANALYSIS: Analyses modelled different levels of programme effectiveness of DOTS and DOTS-plus, and high (10%) and intermediate (3%) proportions of primary multidrug resistant tuberculosis, while accounting for exogenous reinfection. MAIN OUTCOME MEASURE: The cumulative number of tuberculosis deaths per 100 000 population over 10 years.
RESULTS: The model predicted that under DOTS, 276 people would die from tuberculosis (24 multidrug resistant and 252 not multidrug resistant) over 10 years under optimal implementation in an area with 3% primary multidrug resistant tuberculosis. Optimal implementation of DOTS-plus would result in four (1.5%) fewer deaths. If implementation of DOTS-plus were to result in a decrease of just 5% in the effectiveness of DOTS, 16% more people would die with tuberculosis than under DOTS alone. In an area with 10% primary multidrug resistant tuberculosis, 10% fewer deaths would occur under optimal DOTS-plus than under optimal DOTS, but 16% more deaths would occur if implementation of DOTS-plus were to result in a 5% decrease in the effectiveness of DOTS
CONCLUSIONS: Under optimal implementation, fewer tuberculosis deaths would occur under DOTS-plus than under DOTS. If, however, implementation of DOTS-plus were associated with even minimal decreases in the effectiveness of treatment, substantially more patients would die than under DOTS.

Entities:  

Mesh:

Year:  2003        PMID: 12637401      PMCID: PMC151519          DOI: 10.1136/bmj.326.7389.574

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  24 in total

1.  Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy.

Authors: 
Journal:  Int J Tuberc Lung Dis       Date:  2001-01       Impact factor: 2.373

2.  DOTS and DOTS-Plus: what's in a name.

Authors:  K S Lambregts-van Weezenbeek; L B Reichman
Journal:  Int J Tuberc Lung Dis       Date:  2000-11       Impact factor: 2.373

3.  The treatment of multidrug-resistant tuberculosis in Turkey.

Authors:  K Tahaoğlu; T Törün; T Sevim; G Ataç; A Kir; L Karasulu; I Ozmen; N Kapakli
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

4.  A survey of drug-resistant Mycobacterium tuberculosis and its relationship to HIV infection.

Authors:  C W Spellman; K J Matty; S E Weis
Journal:  AIDS       Date:  1998-01-22       Impact factor: 4.177

5.  Recent advances in epidemiological research in tuberculosis.

Authors:  K Styblo
Journal:  Adv Tuberc Res       Date:  1980

6.  Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic.

Authors:  H J Kim; Y P Hong; S J Kim; W J Lew; E G Lee
Journal:  Int J Tuberc Lung Dis       Date:  2001-12       Impact factor: 2.373

Review 7.  Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis.

Authors:  Christopher Dye; Brian G Williams; Marcos A Espinal; Mario C Raviglione
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

8.  Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso.

Authors:  S Ledru; B Cauchoix; M Yaméogo; A Zoubga; J Lamandé-Chiron; F Portaels; J P Chiron
Journal:  Tuber Lung Dis       Date:  1996-10

9.  Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

Authors:  A Pablos-Méndez; M C Raviglione; A Laszlo; N Binkin; H L Rieder; F Bustreo; D L Cohn; C S Lambregts-van Weezenbeek; S J Kim; P Chaulet; P Nunn
Journal:  N Engl J Med       Date:  1998-06-04       Impact factor: 91.245

10.  Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. China Tuberculosis Control Collaboration.

Authors: 
Journal:  Lancet       Date:  1996-02-10       Impact factor: 79.321

View more
  9 in total

1.  Impact of DOTS and DOTS-plus on multidrug resistant TB: DOTS-plus strengthens, not weakens, DOTS programmes.

Authors:  Edward A Nardell
Journal:  BMJ       Date:  2003-07-19

2.  Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs.

Authors:  O S Toungoussova; A O Mariandyshev; G Bjune; D A Caugant; P Sandven
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-03       Impact factor: 3.267

3.  Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study.

Authors:  Sanjay Basu; Jason R Andrews; Eric M Poolman; Neel R Gandhi; N Sarita Shah; Anthony Moll; Prashini Moodley; Alison P Galvani; Gerald H Friedland
Journal:  Lancet       Date:  2007-10-27       Impact factor: 79.321

4.  Cost-effectiveness of treating multidrug-resistant tuberculosis.

Authors:  Stephen C Resch; Joshua A Salomon; Megan Murray; Milton C Weinstein
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

5.  Factors related to adopting healthy behaviors by patients with tuberculosis in Isfahan: Application of health belief model.

Authors:  Maryam Johari; Ahmad Ali Eslami; Hamid Alahverdipoor; Akbar Hasanzade; Fariba Farid
Journal:  J Educ Health Promot       Date:  2014-08-28

6.  A First Insight into the Genetic Diversity and Drug Susceptibility Pattern of Mycobacterium tuberculosis Complex in Zhejiang, China.

Authors:  Zhengwei Liu; Yu Pang; Songhua Chen; Beibei Wu; Haibo He; Aizhen Pan; Xiaomeng Wang
Journal:  Biomed Res Int       Date:  2016-11-22       Impact factor: 3.411

Review 7.  Multidrug-resistant tuberculosis treatment adherence in migrants: a systematic review and meta-analysis.

Authors:  Laura B Nellums; Kieran Rustage; Sally Hargreaves; Jon S Friedland
Journal:  BMC Med       Date:  2018-02-22       Impact factor: 8.775

8.  Bridging the gap between policy and practice: a qualitative analysis of providers' field experiences tinkering with directly observed therapy in patients with drug-resistant tuberculosis in Addis Ababa, Ethiopia.

Authors:  Kirubel Manyazewal Mussie; Christoph Gradmann; Tsegahun Manyazewal
Journal:  BMJ Open       Date:  2020-06-16       Impact factor: 2.692

9.  Evaluation of the Effectiveness of Artificial Neural Network Based on Correcting Scoliosis and Improving Spinal Health in University Students.

Authors:  Jiefu Peng
Journal:  J Healthc Eng       Date:  2022-02-10       Impact factor: 2.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.